Interim Report, January-September 2003

Tripep AB (publ) - Interim Report, January - September 2003 · Result after tax: -SEK 17.2 million (-SEK 38.9 m). Research and development costs: SEK 9.5 million (SEK 11.6 m). The company has no other income. EPS: -SEK 1.30 (-SEK 2.81). · Research into Tripep's new anti-HIV medication, MetaboliteX, continues. · Formation of the jointly owned company VLP Biotech Inc. continues according to plan. Tripep's share of the company is 30%. For additional information, please contact Johan Ihre, CEO Tel: +46 8 449 84 80, mobile: +46 707 33 44 25 e-mail: johan.ihre@tripep.se or Anders Vahlne, Vice President, Head of Research Tel: +46 8 5858 1313, mobile: +46 709 28 05 28 e-mail: anders.vahlne@labmed.ki.se Tripep is a biotech research company that develops and commercialises candidate drugs based on patented technologies: - Research and development of a potential HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines for HIV and hepatitis C, and the RAS® technology platform. For a description of the company's technologies, please see the company's homepage at www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/27/20031027BIT00970/wkr0001.doc Hela rapporten http://www.waymaker.net/bitonline/2003/10/27/20031027BIT00970/wkr0002.pdf Hela rapporten

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe